Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)

China flag China · Delayed Price · Currency is CNY
113.01
+4.79 (4.43%)
Sep 30, 2025, 3:00 PM CST
4.43%
Market Cap29.91B
Revenue (ttm)667.91M
Net Income (ttm)-144.10M
Shares Out264.71M
EPS (ttm)-0.55
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,356,035
Average Volume4,542,342
Open107.55
Previous Close108.22
Day's Range107.50 - 114.65
52-Week Range58.00 - 134.17
Beta0.14
RSI54.73
Earnings DateOct 31, 2025

About SHA:688266

Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 910
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688266
Full Company Profile

Financial Performance

In 2024, SHA:688266's revenue was 532.95 million, an increase of 37.91% compared to the previous year's 386.44 million. Losses were -137.83 million, -50.52% less than in 2023.

Financial Statements

News

There is no news available yet.